Qatar University is strengthening its research ecosystem in pharmacogenomics and AI-driven precision medicine through a pioneering multi-omics study aimed at improving personalized healthcare outcomes in Qatar.

Led by Dr. Kholoud Mohammed Abdulla, the project integrates genomic, transcriptomic, microbiome, proteomic, and metabolomic data with pharmacology to better understand disease mechanisms and support precision treatment development.

Click here to join our WhatsApp channel here

The study also includes Qatar’s first randomized controlled trial applying pharmacogenomics in clinical practice, supported by artificial intelligence and machine learning to enhance clinical decision-making and therapeutic effectiveness.

Supported by the Qatar Research, Development, and Innovation Council (QRDI), the project involves collaborations with Hamad Medical Corporation and Hamad Bin Khalifa University, reinforcing the integration of research and clinical application.

Also read: Middle East University Organises Comprehensive Medical Day to Promote Health Awareness on Campus

Dr. Abdulla emphasized that “The initiative aims to advance evidence-based, data-driven healthcare solutions while building national capacity in medical data sciences and precision medicine, in alignment with Qatar National Vision 2030.”

The research further highlights QU’s contribution to global pharmacogenomics, with Dr. Abdulla’s international recognition through platforms such as PharmGKB/CPIC PGRN, strengthening its position in personalized medicine innovation.